Matthieu Willot

Learn More
Current therapies for common types of cancer such as renal cell cancer are often ineffective and unspecific, and novel pharmacological targets and approaches are in high demand. Here we show the unexpected possibility for the rapid and selective killing of renal cancer cells through activation of calcium-permeable nonselective transient receptor potential(More)
Although successful in many types of cancer, chemotherapy has shown at best moderate effectiveness in the treatment of renal cell carcinoma. Currently approved therapies target the downstream signaling that leads to an over-expression of angiogenic factors such as VEGF and PDGF and include tyrosine kinase inhibitors (sorafenib, sutinib) as well as mTOR(More)
using a flexible solution-based chemical approach — as the size of the metal oxide particles approaches the nanoscale, the high-temperature phase can be supercooled down to room temperature. This metastability coupled with the presence of a hidden thermodynamically stable phase at the same temperature lies at the heart of the observed fascinating(More)